HMGA1 inhibits the function of p53 family members in thyroid cancer cells

Cancer Research

Volumn 66, Issue 6, 2006, Pages 2980-2989

  Frasca, Francesco ^a   Rustighi, Alessandra ^d,e   Malaguarnera, Roberta ^a   Altamura, Sandro ^d   Vigneri, Paolo ^b   Del Sal, Giannino ^d,e   Giancotti, Vincenzo ^d   Pezzino, Vincenzo ^c   Vigneri, Riccardo ^a   Manfioletti, Guidalberto ^d  

^a GARIBALDI HOSPITAL   (Italy)

^b Sc di Spec in Chirugica Vascolare   (Italy)

^c CANNIZZARO HOSPITAL   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e Laboratorio Nazionale CIB   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; PROTEIN P53; PROTEIN TAP63ALPHA; PROTEIN TAP73ALPHA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DELETION MUTANT; DNA BINDING; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALIGNANT TRANSFORMATION; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; THYROID CANCER; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DNA, NEOPLASM; HMGA1A PROTEIN; HUMANS; IMMUNOPRECIPITATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RNA, SMALL INTERFERING; THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33645515483     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2637     Document Type: Article

References (56)

1. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001;277:63-81.
2. Sgarra R, Rustighi A, Tessari MA, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004;574:1-8.
3. Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J Biol Chem 1988;263:18338-42.
4. Manfioletti G, Giancotti V, Bandiera A, et al. cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res 1991;19:6793-7.
5. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439-46.
6. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998; 23:350-7.
7. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-4.
8. Ayoubi TA, Jansen E, Meulemans SM, Van de Ven WJ. Regulation of HMGIC expression: an architectural transcription factor involved in growth control and development. Oncogene 1999;18:5076-87.
9. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-61.
10. Wood LJ, Mukherjee M, Dolde CE, et al. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000;20:5490-502.
11. Treff NR, Pouchnik D, Dement GA, Britt RL, Reeves R. High-mobility group Ala protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells. Oncogene 2004;23:777-85.
12. Treff NR, Dement GA, Adair JE, et al. Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells. Oncogene 2004;23:8557-62.
13. Fedele M, Pentimalli F, Baldassarre G, et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005;24:3427-35.
14. Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002;21:3190-8.
15. Xu Y, Sumter TF, Bhattacharya R, et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004;64:3371-5.
16. Berlingieri MT, Manfioletti G, Santoro M, et al. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 1995;15:1545-53.
17. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, Fusco A. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 2002;21:2971-80.
18. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A 2000;97:4256-61.
19. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-40.
20. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
21. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-56.
22. Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179-84.
23. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
24. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
25. Jost CA, Marin MC, Kaelin WG, Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997;389:191-4.
26. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001;12:337-49.
27. De Laurenzi V, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998;188:1763-8.
28. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999;59:3257-63.
29. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-37.
30. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 2004;24:7987-97.
31. Urist M, Prives C. The linchpin? Pin1 meets p73. Cancer Cell 2004;5:515-7.
32. Gostissa M, Hofmann TG, Will H, Del Sal G. Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol 2003;15:351-7.
33. Malaguarnera R, Mandarino A, Mazzon E, et al. The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer 2005;12:953-71.
34. Frasca F, Vella V, Aloisi A, et al. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 2003;63:5829-37.
35. Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M, Wynford-Thomas D. Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells. Oncogene 1995;10:49-59.
36. Sgarra R, Tessari MA, Di Bernardo J, et al. Discovering high mobility group A molecular partners in tumour cells. Proteomics 2005;5:1494-506.
37. Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 2003;23:9104-16.
38. Sgarra R, Lee J, Tessari MA, et al. The AT-hook of the chromatin architectural transcription factor HMGA1a is arginine methylated by PRMT6. J Biol Chem 2005 [Epub ahead of print].
39. Sandy P, Gostissa M, Fogal V, et al. p53 is involved in the p120E4F-mediated growth arrest. Oncogene 2000;19:188-99.
40. Gostissa M, Morelli M, Mantovani F, et al. The transcriptional represser hDaxx potentiates p53-dependent apoptosis. J Biol Chem 2004;279:48013-23.
41. Rustighi A, Mantovani F, Fusco A, Giancotti V, Manfioletti G. Sp1 and CTF/NF-1 transcription factors are involved in the basal expression of the Hmgi-c proximal promoter. Biochem Biophys Res Commun 1999;265:439-47.
42. Chiappetta G, Bandiera A, Berlingieri MT, et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995;10:1307-14.
43. Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58:4193-8.
44. Brunetti A, Manfioletti G, Chiefari E, Goldfine ID, Foti D. Transcriptional regulation of human insulin receptor gene by the high-mobility group protein HMGI(Y). FASEB J 2001;15:492-500.
45. Chen PL, Chen YM, Bookstein R, Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990;250:1576-80.
46. Podtcheko A, Ohtsuru A, Tsuda S, et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003;88:1889-96.
47. Chene P. The role of tetramerization in p53 function. Oncogene 2001;20:2611-7.
48. Zhao LY, Liu Y, Bertos NR, Yang XJ, Liao D. PCAF is a coactivator for p73-mediated transactivation. Oncogene 2003;22:8316-29.
49. Kim EJ, Park JS, Um SJ. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem 2002;277:32020-8.
50. D'Orazi G, Cecchinelli B, Bruno T, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002;4:11-9.
51. Pierantoni GM, Fedele M, Pentimalli F, et al. High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 2001;20:6132-41.
52. Jayaraman L, Moorthy NC, Murthy KG, et al. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 1998;12:462-72.
53. McKinney K, Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol 2002;22:6797-808.
54. Gotz C, Scholtes P, Prowald A, et al. Protein kinase CK2 interacts with a multi-protein binding domain of p53. Mol Cell Biochem 1999;191:111-20.
55. Imamura T, Izumi H, Nagatani G, et al. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem 2001;276:7534-40.
56. Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 2002;277:7157-64.